ADCENDO
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
ADCENDO
Social Links:
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.adcendo.dk
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
114.58 M USD
Technology used in webpage:
Google Font API WordPress LetsEncrypt Font Awesome Wordpress Plugins LiteSpeed Lightspeed Cache Team.blue Under Construction For WordPress
Similar Organizations
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gilde Healthcare
Gilde Healthcare investment in Series A - ADCendo
RA Capital Management
RA Capital Management investment in Series A - ADCendo
Ysios Capital
Ysios Capital investment in Series A - ADCendo
Novo Holdings
Novo Holdings investment in Series A - ADCendo
Dawn Biopharma
Dawn Biopharma investment in Series A - ADCendo
Pontifax
Pontifax investment in Series A - ADCendo
HealthCap
HealthCap investment in Series A - ADCendo
Novo Holdings
Novo Holdings investment in Series A - ADCendo
RA Capital Management
RA Capital Management investment in Series A - ADCendo
HealthCap
HealthCap investment in Series A - ADCendo
Key Employee Changes
| Date | New article |
|---|---|
| 2023-06-20 | Lone Ottesen named Adcendo CMO |
| 2022-05-03 | Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer |
Official Site Inspections
http://www.adcendo.dk
- Host name: linux25.curanet.dk
- IP address: 185.21.41.51
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "ADCendo"
About Adcendo | Adcendo
About Adcendo. Adcendo is a clinical-stage biotech company dedicated to developing transformative first-in-class ADC therapies for cancers with high unmet medical need. We are …See details»
The Story - Adcendo
Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet. The scientific founders, Niels Behrendt, Lars Engelholm and Christoffer Nielsen from The Finsen Laboratory, had just recently published …See details»
Investments · adcendo - Novo Holdings
Jeroen currently holds several board roles and led the investment in Adcendo and Rappta Therapeutics. Prior to joining Novo, Jeroen worked at M Ventures, the corporate venture capital arm of Merck, where he focused on Seed and Series …See details»
ADCendo - Crunchbase Company Profile & Funding
Contact Email [email protected] ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be …See details»
Adcendo - LinkedIn
Adcendo | 5.426 følgere på LinkedIn. ADCs, Copenhagen, Denmark. | Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet …See details»
Novo Holdings joins $135 million Series B financing for Adcendo
4 days ago Adcendo ApS is a clinical-stage biotechnology company developing breakthrough antibody-drug conjugates, or ADCs, for the treatment of underserved cancers. In 2024, the …See details»
BII alumnus Adcendo raises EUR 51 million - BioInnovation Institute
Apr 29, 2021 In 2017, they co-founded Adcendo with Niels Behrendt and Lars Henning Engelholm. ... DK 2200 Copenhagen N Denmark [email protected] Invoice information. BII …See details»
Novo Holdings · News & Reports · novo-seeds-co …
Apr 29, 2021 About Adcendo ApSAdcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug …See details»
Over DKK 3 billion (USD 413 million) raised by BioInnovation …
Apr 4, 2023 Today, original incubate and portfolio company, Adcendo Aps, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the …See details»
Copenhagen Science City becomes
May 30, 2024 The highly promising biotech start-up Adcendo is one of the first companies to move out of Copenhagen Science City and into ‘Science City-partner Symbions’ new location …See details»
Adcendo Company Profile 2024: Valuation, Funding & Investors
Adcendo General Information Description. Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. The company's …See details»
Our investors - Adcendo
In April 2021, Adcendo ApS closed a series A investment round at 51m EUR, through an international syndicate of leading life science and biotech investors. The round was extended …See details»
Adcendo ApS Completes Oversubscribed $135 Million Series B
4 days ago As part of the financing, the new Adcendo Board of Directors will consist of John Haurum (Chairman), ... Organization Profile. Adcendo. Contact Cision. 866-245-2317 from 8 …See details»
ADCendo Company Profile - Office Locations, Competitors ... - Craft
ADCendo $62 m in total funding,. See insights on ADCendo including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Adcendo raises EUR 51 Million in Series A Financing to Advance …
COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced …See details»
Novo Holdings Co-Leads Adcendo’s Series A Extension to 82M …
Apr 4, 2023 Michael Pehl, Chief Executive Officer of Adcendo, said: “This financing underscores the confidence that our investors have in Adcendo’s capabilities and potential to develop …See details»
Milliardhandel gav Adcendo ny lægemiddelkandidat – nu står den …
3 days ago Den københavnske biotekstartup Adcendo, der holder til hos biotekfællesskabet Symbion, har sat lægemiddelkandidaten ADCE-T02 øverst på prioriteringslisten over mulige …See details»
Adcendo Series A Press Release
Copenhagen, Denmark, 29 April 2021 – Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a …See details»
Adcendo henter 90 mio. kr. til målrettet kræftterapi - medwatch.dk
May 6, 2024 Adcendo henter 90 mio. kr. til målrettet kræftterapi Kliniske forsøg er planlagt til at begynde ved udgangen af 2024. Adcendo udvikler en ny type kræftbehandling, der angriber …See details»